Using PBPK Absorption Modeling to Support Biopharmaceutics Classification System Class 3 Drug Waiver

preview_player
Показать описание
Fang Wu from the Office of Generic Drugs discusses use of physiologically-based pharmacokinetic (PBPK) absorption modeling to support waivers for non-Q1/Q2 BCS class 3 generic drug products.

_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Phone - (301) 796-6707 I (866) 405-5367
  1. U.S. Food and Drug Administration
  2. GDUFA
  3. FDA
  4. CDER
  5. SBIA
  6. Generics
Рекомендации по теме
Using PBPK Absorption 0:15:48

Using PBPK Absorption Modeling to Support Biopharmaceutics Classification System Class 3 Drug Waiver

PBPK Modeling for 1:03:02

PBPK Modeling for Identifying and Mitigating Absorption Risks in Early Drug Development

A Best Practice 0:55:39

A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development

Applying MAM PBPK 1:28:00

Applying MAM PBPK Modeling to Predict Positive Negative Food Effects

PBPK Modeling of 0:58:59

PBPK Modeling of Pulmonary Drug Absorption: Challenges & Perspective

Use of oral 1:22:08

Use of oral absorption modelling to characterize drug release and absorption of a BCS II...

The Use of 0:06:38

The Use of PBPK modeling in Drug Discovery

PBPK modeling and 0:49:40

PBPK modeling and simulation: Bridging the “Bottom Up” and “Top-Down” Approaches

Precision Dosing Using 0:40:57

Precision Dosing Using PBPK Modeling

Human-on-a-Chip combined with 1:04:10

Human-on-a-Chip combined with PBPK modeling for in vitro/in vivo PK/PD extrapolation

Leveraging Dermal PBPK 1:02:16

Leveraging Dermal PBPK Modeling and Simulation Approaches

Unlocking the Power 0:58:18

Unlocking the Power of PBPK Modeling: PBPK for First-in-Human and Beyond

Physiologically Based Pharmacokinetic 0:59:39

Physiologically Based Pharmacokinetic Modelling for First‑In‑Human Predictions

Common Myths about 0:03:39

Common Myths about PBPK Modeling and Simulation- Busted!

Updates to the 0:57:06

Updates to the Simcyp Simulator’s Oral Absorption ADAM and M-ADAM Models

PBPK modeling to 1:01:04

PBPK modeling to assess the impact of diseases on oral drug absorption case study in HIV infected

Applications Experiences of 1:26:54

Applications Experiences of PBPK Modeling to Support Regulatory Interactions

PBPK to Guide 0:19:56

PBPK to Guide Study Design and Product Development for Generic Dermatological Products

Mechanistic In Vitro 1:20:40

Mechanistic In Vitro Dissolution PBPK Models to Drive Drug Development

Applying Mechanistic Modeling 1:49:42

Applying Mechanistic Modeling to Predict Food Effects on Drugs: Approaches & Special Considerati...

First-In-Human (FIH) faster: 0:59:23

First-In-Human (FIH) faster: The Power of Physiologically Based Pharmacokinetic (PBPK) Modeling

Using PBPK M&S 0:57:29

Using PBPK M&S to support the development of an IR tablet formulation

1 Introduction to 0:20:08

1 Introduction to PBPK Modeling

Incorporating transporter kinetics 1:09:09

Incorporating transporter kinetics into PBPK models